{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:23:32Z","timestamp":1790771012658,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","award":["S\/06\/23"],"award-info":[{"award-number":["S\/06\/23"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020218","name":"Chiesi USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03136-9","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:18:40Z","timestamp":1755199120000},"page":"139-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-7563","authenticated-orcid":false,"given":"Angelo","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shneyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Serrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Di Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johny","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sweeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuram","family":"Melarcode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna","family":"Kini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"3136_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ehjcvp\/pvaa107","volume":"7","author":"L De Luca","year":"2020","unstructured":"De Luca L, Valgimigli M (2020) Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. Eur Heart J - Cardiovasc Pharmacotherapy 7:352\u2013359. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa107","journal-title":"Eur Heart J - Cardiovasc Pharmacotherapy"},{"key":"3136_CR2","doi-asserted-by":"publisher","unstructured":"Piccolo R, Oliva A, Avvedimento M, Franzone A, Windecker S, Valgimigli M, Esposito G, J\u00fcni P (2021) Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention 17. https:\/\/doi.org\/10.4244\/EIJ-D-20-01197","DOI":"10.4244\/EIJ-D-20-01197"},{"key":"3136_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","volume":"42","author":"D Cao","year":"2021","unstructured":"Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R (2021) Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 42:339\u2013351. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa824","journal-title":"Eur Heart J"},{"key":"3136_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","volume":"17","author":"M Galli","year":"2024","unstructured":"Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabr\u00f2 P, Terracciano F, Andreotti F, Patti G, De Caterina R et al (2024) Antithrombotic therapy in high bleeding risk, part I: percutaneous cardiac interventions. JACC Cardiovasc Interv 17:2197\u20132215. https:\/\/doi.org\/10.1016\/j.jcin.2024.08.022","journal-title":"JACC Cardiovasc Interv"},{"key":"3136_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","volume":"9","author":"M Valgimigli","year":"2023","unstructured":"Valgimigli M, Aboyans V, Angiolillo D, Atar D, Capodanno D, Halvorsen S, James S, J\u00fcni P, Kunadian V, Landi A et al (2023) Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother 9:462\u2013496. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad032","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3136_CR6","doi-asserted-by":"publisher","first-page":"175394471989327","DOI":"10.1177\/1753944719893274","volume":"13","author":"D Capodanno","year":"2019","unstructured":"Capodanno D, Milluzzo RP, Angiolillo DJ (2019) Intravenous antiplatelet therapies (glycoprotein iib\/iiia receptor inhibitors and cangrelor) in percutaneous coronary intervention: from Pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis 13:1753944719893274. https:\/\/doi.org\/10.1177\/1753944719893274","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"3136_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E et al (2013) Effect of platelet Inhibition with Cangrelor during PCI on ischemic events. N Engl J Med 368:1303\u20131313. https:\/\/doi.org\/10.1056\/NEJMoa1300815","journal-title":"N Engl J Med"},{"key":"3136_CR8","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1093\/eurheartj\/ehy562","volume":"39","author":"GW Stone","year":"2018","unstructured":"Stone GW, G\u00e9n\u00e9reux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J et al (2018) Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor Inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 39:4112\u20134121. https:\/\/doi.org\/10.1093\/eurheartj\/ehy562","journal-title":"Eur Heart J"},{"key":"3136_CR9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D et al (2017) International expert consensus on switching platelet P2Y12 receptor inhibiting therapies. Circulation 136:1955\u20131975. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031164","journal-title":"Circulation"},{"key":"3136_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"SR Steinhubl","year":"2008","unstructured":"Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS (2008) Transitioning patients from Cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527\u2013534. https:\/\/doi.org\/10.1016\/j.thromres.2007.05.020","journal-title":"Thromb Res"},{"key":"3136_CR11","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.jcin.2023.08.009","volume":"16","author":"F Franchi","year":"2023","unstructured":"Franchi F, Rollini F, Ortega-Paz L, Been L, Giordano S, Galli M, Ghanem G, Garabedian H, Al Saleh T, Uzunoglu E et al (2023) Switching from Cangrelor to Prasugrel in patients undergoing percutaneous coronary intervention. JACC: Cardiovasc Interventions 16:2528\u20132539. https:\/\/doi.org\/10.1016\/j.jcin.2023.08.009","journal-title":"JACC: Cardiovasc Interventions"},{"key":"3136_CR12","doi-asserted-by":"publisher","first-page":"e024513","DOI":"10.1161\/JAHA.121.024513","volume":"11","author":"JA Rymer","year":"2022","unstructured":"Rymer JA, Bhatt DL, Angiolillo DJ, Diaz M, Garratt KN, Waksman R, Edwards L, Tasissa G, Salahuddin K, El-Sabae H et al (2022) Cangrelor use patterns and transition to oral P2Y12 inhibitors among patients with myocardial infarction: initial results from the CAMEO registry. J Am Heart Association 11:e024513. https:\/\/doi.org\/10.1161\/JAHA.121.024513","journal-title":"J Am Heart Association"},{"key":"3136_CR13","doi-asserted-by":"publisher","unstructured":"De Luca L, Calabr\u00f2 P, Capranzano P, Di Mario C, Chirillo F, Rolfo C, Menozzi A, Menichelli M, Bolognese L, Musumeci G et al (2023) Safety of Cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study. Eur Heart J Open 3. https:\/\/doi.org\/10.1093\/ehjopen\/oead076","DOI":"10.1093\/ehjopen\/oead076"},{"key":"3136_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/circulationaha.119.040167","volume":"140","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 140:240\u2013261. https:\/\/doi.org\/10.1161\/circulationaha.119.040167","journal-title":"Circulation"},{"key":"3136_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40256-016-0192-1","volume":"17","author":"A Qamar","year":"2017","unstructured":"Qamar A, Bhatt DL (2017) Optimizing the use of Cangrelor in the real world. Am J Cardiovasc Drugs 17:5\u201316. https:\/\/doi.org\/10.1007\/s40256-016-0192-1","journal-title":"Am J Cardiovasc Drugs"},{"key":"3136_CR16","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.jacc.2024.05.084","volume":"84","author":"M Galli","year":"2024","unstructured":"Galli M, Cortellini G, Occhipinti G, Rossini R, Romano A, Angiolillo DJ (2024) Aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 84:1748\u20131766. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.084","journal-title":"J Am Coll Cardiol"},{"key":"3136_CR17","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1055\/s-0040-1721504","volume":"4","author":"R Rossini","year":"2020","unstructured":"Rossini R, Masiero G, Fruttero C, Passamonti E, Calvaruso E, Cecconi M, Carlucci C, Mojoli M, Guido P, Talanas G et al (2020) Antiplatelet therapy with Cangrelor in patients undergoing surgery after coronary stent implantation: A Real-World bridging protocol experience. TH Open 4:e437\u2013e445. https:\/\/doi.org\/10.1055\/s-0040-1721504","journal-title":"TH Open"},{"key":"3136_CR18","doi-asserted-by":"publisher","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","volume":"10","author":"L De Luca","year":"2021","unstructured":"De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ (2021) Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Association 10:e022125. https:\/\/doi.org\/10.1161\/JAHA.121.022125","journal-title":"J Am Heart Association"},{"key":"3136_CR19","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","volume":"139","author":"F Franchi","year":"2019","unstructured":"Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L et al (2019) Platelet Inhibition with Cangrelor and crushed Ticagrelor in patients with ST-Segment\u2013Elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139:1661\u20131670. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038317","journal-title":"Circulation"},{"key":"3136_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jcin.2016.10.004","volume":"10","author":"W Hochholzer","year":"2017","unstructured":"Hochholzer W, Kleiner P, Younas I, Valina CM, L\u00f6ffelhardt N, Amann M, B\u00f6micke T, Ferenc M, Hauschke D, Trenk D et al (2017) Randomized comparison of oral P2Y12-Receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 trial. JACC: Cardiovasc Interventions 10:121\u2013129. https:\/\/doi.org\/10.1016\/j.jcin.2016.10.004","journal-title":"JACC: Cardiovasc Interventions"},{"key":"3136_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","volume":"16","author":"F Franchi","year":"2023","unstructured":"Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, Shalhoub A, Ossi T, Rivas A, Zhou X et al (2023) Cangrelor in patients with coronary artery disease pretreated with Ticagrelor. JACC: Cardiovasc Interventions 16:36\u201346. https:\/\/doi.org\/10.1016\/j.jcin.2022.10.034","journal-title":"JACC: Cardiovasc Interventions"},{"key":"3136_CR22","doi-asserted-by":"publisher","unstructured":"Rymer J, Alhanti B, Kemp S, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Garratt KN, Wimmer NJ, Waksman R et al (2024) Risk of bleeding among Cangrelor-Treated patients administered upstream P2Y12 inhibitor therapy: the CAMEO registry. J Soc Cardiovasc Angiography Interventions 3. https:\/\/doi.org\/10.1016\/j.jscai.2023.101202","DOI":"10.1016\/j.jscai.2023.101202"},{"key":"3136_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.4244\/eij-d-24-00757","volume":"21","author":"G Gargiulo","year":"2025","unstructured":"Gargiulo G, Cirillo P, Sperandeo L, Castiello DS, Manzi L, Forzano I, Florimonte D, Simonetti F, Canonico ME, Avvedimento M et al (2025) Pharmacodynamic effects of Cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII registry. EuroIntervention 21:560\u2013570. https:\/\/doi.org\/10.4244\/eij-d-24-00757","journal-title":"EuroIntervention"},{"key":"3136_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.4244\/eij-d-22-00594","volume":"18","author":"G Gargiulo","year":"2023","unstructured":"Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F et al (2023) Pharmacodynamic effects of Cangrelor in elective complex PCI: insights from the POMPEII registry. EuroIntervention 18:1266\u20131268. https:\/\/doi.org\/10.4244\/eij-d-22-00594","journal-title":"EuroIntervention"},{"key":"3136_CR25","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cardfail.2024.08.003","volume":"30","author":"J Rymer","year":"2024","unstructured":"Rymer J, Pichan C, Page C, Alhanti B, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Wimmer NJ, Waksman RON et al (2024) The use of Cangrelor in cardiogenic shock: insights from the CAMEO registry. J Card Fail 30:1233\u20131240. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.003","journal-title":"J Card Fail"},{"key":"3136_CR26","doi-asserted-by":"publisher","first-page":"e1309","DOI":"10.4244\/EIJ-D-24-00203","volume":"20","author":"Z Motovska","year":"2024","unstructured":"Motovska Z, Hlinomaz O, Mrozek J, Kala P, Geisler T, Hromadka M, Akin I, Precek J, Kettner J, Cervinka P et al (2024) Cangrelor versus crushed Ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention 20:e1309\u2013e1318. https:\/\/doi.org\/10.4244\/EIJ-D-24-00203","journal-title":"EuroIntervention"},{"key":"3136_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.23736\/s2724-5683.21.05669-6","volume":"70","author":"M Galli","year":"2022","unstructured":"Galli M, Migliaro S, Rodolico D, Piccinni GDIS, Restivo C, Andreotti A, Vergallo F, Montone R, Besis RA (2022) Intracoronary bolus of glycoprotein iib\/iiia inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of ST-elevation myocardial infarction. Minerva Cardiol Angiol 70:697\u2013705. https:\/\/doi.org\/10.23736\/s2724-5683.21.05669-6","journal-title":"Minerva Cardiol Angiol"},{"key":"3136_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2147\/pgpm.S391400","volume":"16","author":"A Oliva","year":"2023","unstructured":"Oliva A, Cao D, Spirito A, Nicolas J, Pileggi B, Kamaleldin K, Vogel B, Mehran R (2023) Personalized approaches to antiplatelet treatment for cardiovascular diseases: an umbrella review. Pharmgenomics Pers Med 16:973\u2013990. https:\/\/doi.org\/10.2147\/pgpm.S391400","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03136-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03136-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03136-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:41:46Z","timestamp":1770644506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03136-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3136"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03136-9","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"11 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mehran reports institutional research payments from Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, CPC Clinical Research, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess Fund Management, and Sanofi US Services, Inc.; personal fees from Elixir Medical, IQVIA, Medtronic, Medscape\/WebMD Global, and NovoNordisk; and equity (\u2009<\u20091%) in Elixir Medical, Stel, and ControlRad (spouse). She reports no fees from SCAI (Women in Innovations Committee Member), the Cardiovascular Research Foundation (CRF), and Women as One (Founding Director). She receives honoraria from the American Medical Association (JAMA Cardiology, Associate Editor) and the American College of Cardiology (Board of Trustees Member, Science Council Member, CTR Program). Dr. Bay is supported by a grant from the German Heart Foundation (Grant number S\/06\/23). Other authors have no relevant conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The SMILE study is an investigator-sponsored study conducted at Mount Sinai Hospital (New York, USA) and is supported by Chiesi Inc. (USA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}